Related Experiment Videos
Polyarthritis and angioimmunoblastic lymphadenopathy.
N J McHugh1, G J Campbell, J J Landreth
1Wellington Regional Rheumatic Diseases Unit, Hutt Hospital, Lower Hutt, New Zealand.
Annals of the Rheumatic Diseases
|July 1, 1987
Summary
Angioimmunoblastic lymphadenopathy (AILD) with polyarthritis showed reduced CDT8 T lymphocytes. Levamisole effectively controlled arthritis and normalized CDT8 levels, supporting T cell regulation defects in AILD.
Area of Science:
- Immunology
- Rheumatology
- Hematology
Background:
- Angioimmunoblastic lymphadenopathy (AILD) is a lymphoproliferative disorder.
- Peripheral polyarthritis is a known clinical manifestation of AILD.
Observation:
- A case of AILD presenting with symmetrical non-erosive peripheral polyarthritis was analyzed.
- Synovial fluid and synovium histology were examined.
- Reduced numbers of peripheral blood T lymphocytes with the CDT8 phenotype were observed in both blood and synovial fluid.
Findings:
- The patient's arthritis was resistant to corticosteroids, causing significant side effects.
- Weekly administration of Levamisole (150 mg) effectively managed the arthritis.
- Levamisole treatment normalized the levels of CDT8 lymphocytes.
Implications:
- The findings support the hypothesis of a T cell regulation defect, specifically in T cell suppression, underlying AILD.
- Reduced CDT8 lymphocytes may be a key indicator in AILD pathogenesis.
- Levamisole shows potential as an effective treatment for AILD-associated polyarthritis.